UBS analyst David Lai lowered the firm’s price target on Perspective Therapeutics (CATX) to $7 from $18 and keeps a Buy rating on the shares.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CATX:
- Buy Rating Affirmed for Perspective Therapeutics Amid Promising Developments in VMT-α-NET Program
- Perspective Therapeutics price target lowered to $7 from $18 at UBS
- Perspective Therapeutics price target lowered to $11 from $12 at B. Riley
- Perspective Therapeutics Reports Q3 2025 Results and Clinical Progress
- Positive Outlook for Perspective Therapeutics Amidst Key Catalysts and Financial Resilience